Core Viewpoint - The announcement by Wanbangde regarding its Alzheimer's disease project being selected for a national major science and technology project highlights the company's commitment to addressing a significant global health challenge and its recognition in the field of innovative drug development [1][2][3] Group 1: Project Details - Wanbangde Pharmaceutical's Alzheimer's disease project has been approved under the National Major Science and Technology Project for Innovative Drug Development, led by the Shanghai Institute of Materia Medica [1] - The project focuses on the industrialization and clinical research of "Shisuanjianjia Controlled-release Tablets," which is a key component of the clinical evaluation and research of new varieties [1][2] Group 2: Market Context - There are nearly 17 million Alzheimer's disease and related dementia patients in China, indicating a significant market need for innovative treatments [2] - Shisuanjianjia injection, a first-line medication for dementia-related memory disorders, has received multiple national awards and patents in various countries, showcasing its established presence in the market [2] Group 3: Clinical Research - The ongoing large-scale, high-quality Phase II/III clinical study of Shisuanjianjia Controlled-release Tablets employs a multi-center, randomized, double-blind design with placebo and positive control groups to comprehensively evaluate efficacy and safety [2] - This study is notable for being the first in China to set dual primary efficacy endpoints and to utilize Aβ-PET imaging to observe changes in amyloid protein deposition [2] Group 4: Company Impact - The inclusion of Shisuanjianjia Controlled-release Tablets in the national major science and technology project reflects the recognition of its potential clinical value and Wanbangde's research capabilities in the field [3] - The successful implementation of this research task is expected to enhance the company's technical level and market competitiveness in the development of drugs for neurological diseases, positively impacting the clinical development and industrialization of its pipeline products [3]

Core Viewpoint - Wanbangde Pharmaceutical's Alzheimer's project has been selected for a national major science and technology project led by the Shanghai Institute of Materia Medica, indicating strong governmental support for innovative drug development in China [1][2] Group 1: Project Details - Wanbangde Pharmaceutical's subsidiary has received approval from the National Health Commission for its Alzheimer's disease project, which is part of a national major science and technology project aimed at developing innovative drugs for high-prevalence diseases [1] - The project focuses on the industrialization and clinical research of "Shisuanjianma Controlled Release Tablets," which is a key component of the clinical evaluation and innovative product research [1][2] Group 2: Market Context - There are nearly 17 million Alzheimer's disease and related dementia patients in China, highlighting a significant market need for effective treatments [2] - The national major science and technology project aims to encourage the development of urgently needed innovative drugs and establish a self-controlled national drug research and development system [1][2] Group 3: Clinical Research - The clinical research for Shisuanjianma Controlled Release Tablets is currently in a large-scale, high-quality Phase II/III trial, designed as a multi-center, randomized, double-blind study with placebo and positive control groups [2] - This study is notable for being the first in China to set dual primary efficacy endpoints and to use Aβ-PET imaging to observe amyloid protein deposition changes, which will help assess the drug's potential to delay disease progression [2] Group 4: Implications for the Company - The inclusion of Shisuanjianma Controlled Release Tablets in the national major science and technology project reflects recognition of its potential clinical value and Wanbangde Pharmaceutical's capabilities in drug development and clinical research [2] - Successful implementation of the research tasks is expected to enhance the company's technological level and market competitiveness in the field of neurodegenerative disease drug development, positively impacting the clinical development and industrialization of its pipeline drugs [2]

Core Viewpoint - Wanbangde Pharmaceutical's Alzheimer's project has been selected for a national major science and technology project led by the Shanghai Institute of Materia Medica, indicating strong governmental support for innovative drug development in China [1][2] Group 1: Project Details - Wanbangde Pharmaceutical's subsidiary has received approval for its Alzheimer's disease project under the national major science and technology project, which focuses on breakthroughs in core technologies and the development of strategic products [1] - The project aims to address the urgent clinical needs for innovative drugs targeting major chronic diseases, infectious diseases, and rare diseases [1] Group 2: Clinical Research - The company is developing a new drug, Shisuanjianma Controlled-Release Tablets, specifically for Alzheimer's disease, which is currently undergoing large-scale, high-quality Phase II/III clinical trials [2] - The clinical study employs a multi-center, randomized, double-blind, and placebo-controlled design, aiming to comprehensively evaluate the drug's efficacy and safety [2] - This study is notable for being the first in China to set dual primary efficacy endpoints and to utilize Aβ-PET imaging to observe amyloid protein deposition changes [2] Group 3: Implications for the Company - The inclusion of Shisuanjianma Controlled-Release Tablets in the national major science and technology project reflects the recognition of its potential clinical value and the company's research capabilities in the field [2] - This project is expected to enhance the company's technological level and market competitiveness in the development of drugs for neurological diseases [2] - Successful implementation of the research tasks will facilitate the comprehensive execution of related innovative drug clinical trials, ultimately benefiting a large number of Alzheimer's patients [2]

Core Viewpoint - Wanbangde's subsidiary, Wanbangde Pharmaceutical Group, has been selected for a national major science and technology project led by the Shanghai Institute of Materia Medica of the Chinese Academy of Sciences, focusing on innovative drug development for Alzheimer's disease [1] Group 1 - The Alzheimer's disease project involves the development of a new drug, Shisuanjianma Controlled-Release Tablets, which is currently undergoing large-scale, high-quality key registration Phase II/III clinical studies [1]

Core Viewpoint - Wanbangde's subsidiary has been selected for a significant national project focused on innovative drug development for Alzheimer's disease, indicating a strategic advancement in the company's research capabilities [1] Group 1 - Wanbangde Pharmaceutical Group has been awarded a project under the National Major Science and Technology Project for Innovative Drug Development led by the Shanghai Institute of Materia Medica, Chinese Academy of Sciences [1] - The project has received formal approval from the National Health Commission's China Biotechnology Development Center, highlighting governmental support for the initiative [1]

Core Viewpoint - Yifan Pharmaceutical has signed an exclusive agreement for the commercialization of ACT001, a first-in-class drug developed by Shangde Yaoyuan, targeting small cell lung cancer brain metastases, marking a significant step in the company's innovation and internationalization strategy [1][2]. Group 1: Agreement Details - Yifan Pharmaceutical's subsidiary, Yifan Pharmaceutical Co., will pay a total of 100 million yuan as an upfront payment, with options for either a cornerstone investment of 100 million yuan or a milestone payment of 50 million yuan, along with a tiered revenue-sharing model [1]. - The agreement covers exclusive commercialization rights in mainland China and surrounding regions, including South Korea and Southeast Asia, leveraging Yifan's existing registration and sales network in Southeast Asia [3]. Group 2: Product and Market Potential - ACT001 has received "breakthrough therapy" designation from the National Medical Products Administration and is currently in Phase III clinical trials, showing significant clinical advantages by enhancing the efficacy of chemotherapy and immunotherapy [2]. - The drug addresses a critical clinical need in the treatment of small cell lung cancer brain metastases, where existing treatment options are limited, potentially leading to improved patient outcomes [2][3]. Group 3: Strategic Implications - This collaboration is seen as a practical step for Yifan Pharmaceutical to integrate innovative products into its portfolio, enhancing its capabilities in research, production, registration, and sales [2]. - While the transaction may increase short-term expenditures, successful commercialization of ACT001 is expected to contribute to sustainable business growth and performance in the long run [3].

Core Viewpoint - Xian Xintong Pharmaceutical Research Co., Ltd. (referred to as "Xintong Pharmaceutical") is attempting a second IPO on the Sci-Tech Innovation Board after its previous attempt failed due to the expiration of the registration approval, despite having a core product that has recently been launched. The company remains unprofitable, and its fundraising target has decreased from 12.79 billion to 9 billion yuan [1][6]. Group 1: Company Overview - Xintong Pharmaceutical is a high-tech enterprise focused on drug research and development for over 20 years, specializing in major liver diseases such as hepatitis B, metabolic dysfunction-related fatty liver disease, and liver cancer [3]. - The company has developed into a competitive player in the liver disease new drug development sector, aiming to meet unmet clinical needs with innovative drugs that have independent intellectual property rights [3]. Group 2: IPO History - The first IPO attempt was accepted on December 6, 2021, but faced delays and ultimately failed to issue shares due to the expiration of the registration approval on April 25, 2023 [2][4]. - The current IPO application has been accepted, and the company is again applying under the fifth set of listing standards, which focus on technological advancement and research capabilities rather than short-term financial metrics [4][5]. Group 3: Financial Performance - Xintong Pharmaceutical has not achieved profitability, with net losses projected at -53.87 million yuan for 2022, -62.29 million yuan for 2023, -79.36 million yuan for 2024, and -13.20 million yuan for the first half of 2025, totaling cumulative losses of approximately 346 million yuan [5]. - Revenue figures for the years 2022 to 2025 show minimal growth, with revenues of approximately 1.10 million yuan in 2022, 11.98 million yuan in 2023, 3.02 million yuan in 2024, and 9.77 million yuan in the first half of 2025 [7]. Group 4: Fundraising and Investment - The current IPO aims to raise 9 billion yuan, allocated to new drug research projects (5 billion yuan), the construction of an innovative drug production base (2 billion yuan), and working capital (2 billion yuan) [6]. - Compared to the previous IPO, the fundraising amount has decreased significantly, with the new drug research project seeing a notable reduction in investment [6]. Group 5: Research and Development - R&D expenses have sharply declined, with figures of 53.23 million yuan in 2022, 62.10 million yuan in 2023, and 26.08 million yuan in 2024, with a further drop to 12.69 million yuan in the first half of 2025 [8][9]. - The decrease in R&D spending is attributed to reduced trial costs and the completion of certain clinical phases, which has raised concerns about the potential slowdown in new drug development and core competitiveness [8][9].

Core Insights - The collaboration between Insilico Medicine and Haizheng Pharmaceutical has achieved a significant milestone by nominating a preclinical candidate compound (PCC) within approximately 8 months of their strategic partnership [1][2][3] Group 1: Collaboration Details - The partnership began in April 2025, focusing on innovative drug development through the integration of AI technology and traditional drug discovery methods [1] - Insilico Medicine is responsible for early-stage research, including target identification, lead compound discovery, and preclinical studies, while Haizheng Pharmaceutical will handle the clinical trial application and subsequent clinical trial processes [1][2] Group 2: Project Progress and Impact - Within the 8-month collaboration, Insilico Medicine efficiently advanced the early research and completed the necessary preclinical studies, meeting the PCC nomination standards set by both companies [2] - The project highlights the potential of AI-driven innovation in drug development, particularly in addressing unmet clinical needs in novel target areas [2][3] Group 3: Strategic Implications - The successful nomination of the PCC within a short timeframe validates the delivery capabilities of Insilico Medicine and the collaborative efficiency of both companies [3] - This collaboration serves as a representative case for local enterprises exploring new pathways in drug development through the synergy of AI platforms and pharmaceutical industrialization capabilities [3]

Group 1 - The collaboration between Insilico Medicine and Haizheng Pharmaceutical has achieved a milestone by nominating a preclinical candidate compound (PCC) within approximately 8 months of their strategic partnership [1][2] - The partnership began in April 2025, focusing on deep collaboration in drug discovery and development by integrating AI technology with traditional drug development advantages [1] - Insilico Medicine is responsible for early-stage research, including target identification, lead compound discovery, and preclinical studies, while Haizheng Pharmaceutical will handle clinical trial application support and subsequent clinical trial implementation [1] Group 2 - Insilico Medicine's Pharma.AI platform has efficiently advanced early-stage research, producing preclinical data that meets the PCC nomination standards set by both companies [2] - The rapid achievement of the PCC nomination demonstrates the potential of AI-driven innovation in early drug development, particularly in addressing unmet clinical needs [2][3] - Haizheng Pharmaceutical expressed strong impressions regarding the efficiency and quality of the project, highlighting the integration of traditional pharmaceutical experience with cutting-edge AI technology as a key step in their digital transformation [3]

Grand Pharmaceutical Group Limited 遠大醫藥集團有限公司* 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而 產生或因倚賴該等內容而引致的任何損失承擔任何責任。 ( 於百慕達註冊成立之有限公司 ) (股份代號：00512) 本集團引進的全球首款用於治療嚴重過敏反應的腎上腺素鼻噴霧劑 獲頒發藥品註冊證書 本公告乃遠大醫藥集團有限公司(「本公司」，連同其附屬公司統稱「本集團」)之董事會 (「董事會」)自願刊發。 董事會欣然公告，近日，本集團通過與祐兒醫藥合作獲得的全球首款用於緊急治療成人和 30kg 及以上兒童患者（2mg 規格）I 型過敏反應（包括嚴重過敏反應）的腎上腺素鼻噴霧 劑 Neffy® (「優敏速® 」)獲得中華人民共和國國家藥品監督管理局（中國藥監局）頒發藥 品註冊證書，本集團擁有該產品在中國大陸合作渠道內的獨家商業化權益以及在中國香 港特別行政區的非獨家商業化權益，並計劃在產品獲批後的 24 個月之內實現本地化生產。 優敏速®是首個被美國食品藥品監督管理局(「 ...